Drug recall · March 30, 2022
NAD+ Nicotinamide Adenine Dinucleotide recall
Why: Product found to be Sub Potent or Exceeded reconstitution time
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
NAD+ Nicotinamide Adenine Dinucleotide, Lyophilized powder for reconstitution, Multi-Dose 500 mg per vial, Each ML contains: 0.288% Sodium Phosphate Monobasic USP, 0.42% Sodium Phosphate Dibasic USP, 5% Mannitol USP, Sterile Water for Injection USP, Rx Only, Olympia Pharmaceuticals 6700 Conroy Rd., Ste. 155, Orlando, FL 32835 NDC: 73198-0083-00
- Lots / codes
Lot: D24005 Exp. 4/5/22; C41008 Exp. 3/8/22
- Quantity
- 2634 vials
- Company
- Olympia Compounding Pharmacy dba Olympia Pharmacy, Orlando, FL
- Distribution
- Nationwide in the USA including Puerto Rico.
- Initiated
- March 8, 2022 · Voluntary: Firm initiated
- Classified
- March 29, 2022
- Reported
- March 30, 2022
- Ended
- October 4, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Mannitol
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.